Biomarkers in Polycystic Kidney Disease: Are We There?
暂无分享,去创建一个
[1] J. Klawitter,et al. Kynurenines in polycystic kidney disease , 2022, Journal of Nephrology.
[2] J. D. de Fijter,et al. Change in Urinary Myoinositol/Citrate Ratio Associates with Progressive Loss of Renal Function in ADPKD Patients , 2022, American Journal of Nephrology.
[3] M. Rudnicki,et al. Coregulation Analysis of Mechanistic Biomarkers in Autosomal Dominant Polycystic Kidney Disease , 2021, International journal of molecular sciences.
[4] J. Klawitter,et al. Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease , 2021, Scientific Reports.
[5] R. Gansevoort,et al. Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression. , 2021, Clinical journal of the American Society of Nephrology : CJASN.
[6] D. Landsittel,et al. Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease , 2021, Kidney international reports.
[7] Enrico Longato,et al. A practical perspective on the concordance index for the evaluation and selection of prognostic time-to-event models , 2020, J. Biomed. Informatics.
[8] D. Landsittel,et al. The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. , 2020, JCI insight.
[9] J. D. de Fijter,et al. Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease. , 2020, Kidney international.
[10] M. Chonchol,et al. KIM-1 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease: HALT-PKD Results , 2020, American Journal of Nephrology.
[11] J. D. de Fijter,et al. Urinary metabolites associate with the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease , 2020, PloS one.
[12] Y. Pei,et al. Global microRNA profiling in human urinary exosomes reveals novel disease biomarkers and cellular pathways for autosomal dominant polycystic kidney disease. , 2020, Kidney international.
[13] R. Gansevoort,et al. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. , 2019, Kidney international.
[14] D. Landsittel,et al. Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease. , 2019, Journal of the American Society of Nephrology : JASN.
[15] D. Landsittel,et al. Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease. , 2019, Kidney international.
[16] R. Perrone,et al. Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[17] A. Chapman,et al. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course , 2019, BMC Nephrology.
[18] Bonnie L Bullock,et al. CD8+ T cells modulate autosomal dominant polycystic kidney disease progression , 2018, Kidney international.
[19] C. Podrini,et al. Metabolism and mitochondria in polycystic kidney disease research and therapy , 2018, Nature Reviews Nephrology.
[20] Nancy R Cook,et al. Quantifying the added value of new biomarkers: how and how not , 2018, Diagnostic and Prognostic Research.
[21] Robert M Califf,et al. Biomarker definitions and their applications , 2018, Experimental biology and medicine.
[22] D. Landsittel,et al. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. , 2017, Kidney international.
[23] J. Burgerhof,et al. Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression , 2017, Kidney international reports.
[24] Kaleab Z. Abebe,et al. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. , 2017, Clinical journal of the American Society of Nephrology : CJASN.
[25] R. Gansevoort,et al. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[26] C. Llorens-Cortes,et al. Role of the Vasopressin/Apelin Balance and Potential Use of Metabolically Stable Apelin Analogs in Water Metabolism Disorders , 2017, Front. Endocrinol..
[27] R. Gansevoort,et al. Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. , 2017, Journal of the American Society of Nephrology : JASN.
[28] R. Gansevoort,et al. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. , 2016, Nephrology, Dialysis and Transplantation.
[29] Johannes B Reitsma,et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration , 2016, BMJ Open.
[30] R. Gansevoort,et al. Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial , 2016, Kidney international reports.
[31] K. Bae,et al. Urine peptidome analysis predicts risk of end‐stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[32] R. Gansevoort,et al. Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[33] I. Kocyiğit,et al. Evaluation of Fibrosis Markers: Apelin and Transforming Growth Factor‐β1 in Autosomal Dominant Polycystic Kidney Disease Patients , 2016, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[34] S. Bakker,et al. Urine and Plasma Osmolality in Patients with Autosomal Dominant Polycystic Kidney Disease: Reliable Indicators of Vasopressin Activity and Disease Prognosis? , 2015, American Journal of Nephrology.
[35] D G Altman,et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): the TRIPOD Statement , 2015, The British journal of surgery.
[36] M. Buemi,et al. Apelin and copeptin: Two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease , 2013, Peptides.
[37] J. Li,et al. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[38] D. Wallace,et al. Macrophages promote polycystic kidney disease progression , 2013, Kidney international.
[39] A. Boletta,et al. Defective Glucose Metabolism in Polycystic Kidney Disease Identifies A Novel Therapeutic Paradigm , 2016 .
[40] C. Ahn,et al. Urinary N-acetyl-β-D glucosaminidase as a surrogate marker for renal function in autosomal dominant polycystic kidney disease: 1 year prospective cohort study , 2012, BMC Nephrology.
[41] Yasunori Sato,et al. Study Designs and Statistical Analyses for Biomarker Research , 2012, Sensors.
[42] L. Bankir,et al. Polycystic kidney disease: An early urea-selective urine-concentrating defect in ADPKD , 2012, Nature Reviews Nephrology.
[43] R. Gansevoort,et al. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment. , 2012, Clinical journal of the American Society of Nephrology : CJASN.
[44] Douglas Landsittel,et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. , 2012, Clinical journal of the American Society of Nephrology : CJASN.
[45] S. Somlo,et al. Evaluation of urine biomarkers of kidney injury in Polycystic Kidney Disease , 2012, Kidney international.
[46] L. Cantley,et al. Macrophages promote cyst growth in polycystic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.
[47] Diego R. Martín,et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[48] Carmine Zoccali,et al. Statistical methods for the assessment of prognostic biomarkers (Part I): discrimination. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[49] Daniel J Sargent,et al. Predictive biomarker validation in practice: lessons from real trials , 2010, Clinical trials.
[50] F. Harrell,et al. Criteria for Evaluation of Novel Markers of Cardiovascular Risk: A Scientific Statement From the American Heart Association , 2009, Circulation.
[51] Holly Janes,et al. Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design , 2008, Journal of the National Cancer Institute.
[52] C. Florkowski. Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests. , 2008, The Clinical biochemist. Reviews.
[53] Bernard F King,et al. Volume progression in polycystic kidney disease. , 2006, The New England journal of medicine.
[54] S. Nagao,et al. Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats. , 2001, Kidney international.
[55] Bradley J Erickson,et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. , 2015, Journal of the American Society of Nephrology : JASN.
[56] D. Hosmer,et al. A review of goodness of fit statistics for use in the development of logistic regression models. , 1982, American journal of epidemiology.